Bologna

• A trial to learn how well surovatamig (AZD0486) works and how safe it is in adults with certain blood cancers Recruiting
  2023-505789-27-00 4 2025-04-14 Relapsed or Refractory Non-Hodgkin Lymphoma
• A trial to learn how well saruparib with camizestrant works and how safe it is in adults with advanced breast cancer that is hormone recepto … Recruiting
  2023-504180-16-00 5 2025-04-07 Advanced Breast Cancer
• Ivosidenib in participants with locally advanced or metastatic conventional chondrosarcoma untreated or previously treated with 1 or 2 syste … Recruiting
  2023-508507-20-00 5 2025-04-03 Locally advanced or metastatic conventional chondrosarcoma with an IDH
• Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell L … Recruiting
  2022-501489-24-00 5 2025-03-28 First-line treatment of adult subjects with high-risk large B-cell lym
• A study in newly diagnosed glioblastoma patients that aims at testing the efficacy of Optune (Tumor Treating Fields), together with temozolo … Recruiting
  2024-513550-30-00 5 2025-03-28 Newly diagnosed Glioblastoma
• A Phase II Study of Ensifentrine in Non-Cystic Fibrosis Bronchiectasis Recruiting
  2024-514845-12-00 4 2025-03-28 Non-Cystic Fibrosis Bronchiectasis
• A study to investigate changes in symptoms in adult participants with chronic rhinosinusitis with nasal polyposis initiating treatment with … Recruiting
  2024-513862-20-00 5 2025-03-26 Chronic Rhinosinusitis with Nasal Polyposis
• Elacestrant versus Standard Endocrine Therapy in Women and Men with Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast C … Recruiting
  2024-515445-42-00 5 2025-03-24 Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast
• KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors Recruiting
  2024-513285-19-00 1 2025-03-14 Pancreatic Ductal Adeno Carcinoma
• A Phase I/II with Ruxolitinib in Patients with Myelofibrosis (MF) who are Unresponsive to JAK inhibitors (HEMA-MED) Recruiting
  2024-515252-20-00 9 2025-03-14 Myelofibrosis (MF) unresponsive to JAK inhibitors
• Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant Recruiting
  2024-513547-82-00 5 2025-03-11 Transthyretin Amyloidosis
• A Phase 2, Placebo-Controlled, Randomized, Double-Blind Study of 2 Doses of Crofelemer for the Treatment of adult patients with Short Bowel … Recruiting
  2024-511994-31-00 4 2025-03-10 Short Bowel Syndrome and Intestinal Failure (SBS-IF) without colon-in-
• Lutathera for the treatment of recurrent Meningioma (LUMEN-1) Recruiting
  2024-513443-93-00 4 2025-03-10 Recurrent Meningioma without local treatment options (Surgery or Radio
• FDG-PET/CT versus conventional CT for response monitoring in metastatic breast cancer: a multicenter randomized clinical trial (MONITOR-RCT) Recruiting
  2023-508591-11-00 5 2025-02-25 Metastatic breast cancer
• A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Axatilimab (INCA034176) and Corticosteroids as Initial Treatment for Chroni … Recruiting
  2023-510292-65-00 5 2025-02-25 chronic graft-versus-host disease
• A randomized, phase II/III trial on the biological and clinical effects of acetyl-L-carnitine in ALS Recruiting
  2023-509853-29-00 10 2025-02-24 amyotrophic lateral sclerosis
• Clinical trial of molnupiravir (MK-4482) in adults who have COVID-19 and are not hospitalized, who are at high risk for serious illness from … Recruiting
  2023-507227-36-00 5 2025-02-21 SARS-CoV-2 (COVID-19) infection
• “A Phase II trial of atezolizumab plus CArboplatin plus nab-Paclitaxel as first-line Therapy in metastatic triple-negative PD-L1 positive br … Recruiting
  2024-519514-31-00 4 2025-01-31 metastatic triple-negative PD-L1 positive breast cancer
• A Multi-centered, Double-blind, Randomized, Placebo-controlled Study of TEV-56286 for the Treatment of Multiple System Atrophy Recruiting
  2023-505320-54-00 4 2025-01-30 Multiple System Atrophy
• Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease ( ENHANCE-CD ) Recruiting
  2023-508234-34-00 4 2025-01-27 Crohn's disease
• Continued PD-L1 inhibition with atezolizumab with rechallenge chemotherapy in patients with sensitive relapse SCLC progressing on first-line … Recruiting
  2024-511945-20-00 4 2025-01-24 patients affected by small cell lung cancer (SCLC)
• A study to assess how Vaborem® is taking up in the body and tolerated in paediatric patients with serious infections. Recruiting
  2024-514656-32-00 4 2025-01-23 Suspected or confirmed Gram negative infections
• ZELA trial: Phase 2b/3 Multicenter Study to Evaluate the Efficacy and Safety of Zelpultide Alfa in Preterm Neonates at High Risk of Developi … Recruiting
  2024-513420-41-00 10 2025-01-09 prematurity in neonates
• Olaparib beyond progression compared to platinum chemotherapy after secondary cytoreductive surgery in recurrent ovarian cancer patients. Th … Recruiting
  2024-516842-21-00 5 2025-01-09 Recurrent ovarian cancer

Showing 265–288 of 868 trials